Animal models for analysis of immunological responses to nanomaterials: Challenges and considerations

William C. Zamboni, J. Szebeni, Serguei V. Kozlov, Andrew T. Lucas, Joseph A. Piscitelli, Marina A. Dobrovolskaia

Research output: Article

6 Citations (Scopus)

Abstract

Nanotechnology provides many solutions to improve conventional drug delivery and has a unique niche in the areas related to the specific targeting of the immune system, such as immunotherapies and vaccines. Preclinical studies in this field rely heavily on the combination of in vitro and in vivo methods to assess the safety and efficacy of nanotechnology platforms, nanoparticle-formulated drugs, and vaccines. While certain types of toxicities can be evaluated in vitro and good in vitro–in vivo correlation has been demonstrated for such tests, animal studies are still needed to address complex biological questions and, therefore, provide a unique contribution to establishing nanoparticle safety and efficacy profiles. The genetic, metabolic, mechanistic, and phenotypic diversity of currently available animal models often complicates both the animal choice and the interpretation of the results. This review summarizes current knowledge about differences in the immune system function and immunological responses of animals commonly used in preclinical studies of nanomaterials. We discuss challenges, highlight current gaps, and propose recommendations for animal model selection to streamline preclinical analysis of nanotechnology formulations.

Original languageEnglish
JournalAdvanced Drug Delivery Reviews
DOIs
Publication statusAccepted/In press - jan. 1 2018

Fingerprint

Nanotechnology
Nanostructures
Animal Models
Nanoparticles
Immune System
Vaccines
Safety
Pharmaceutical Preparations
Immunotherapy
In Vitro Techniques

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Animal models for analysis of immunological responses to nanomaterials : Challenges and considerations. / Zamboni, William C.; Szebeni, J.; Kozlov, Serguei V.; Lucas, Andrew T.; Piscitelli, Joseph A.; Dobrovolskaia, Marina A.

In: Advanced Drug Delivery Reviews, 01.01.2018.

Research output: Article

Zamboni, William C. ; Szebeni, J. ; Kozlov, Serguei V. ; Lucas, Andrew T. ; Piscitelli, Joseph A. ; Dobrovolskaia, Marina A. / Animal models for analysis of immunological responses to nanomaterials : Challenges and considerations. In: Advanced Drug Delivery Reviews. 2018.
@article{837e28ee2aa64a5096f9cd12066d11cb,
title = "Animal models for analysis of immunological responses to nanomaterials: Challenges and considerations",
abstract = "Nanotechnology provides many solutions to improve conventional drug delivery and has a unique niche in the areas related to the specific targeting of the immune system, such as immunotherapies and vaccines. Preclinical studies in this field rely heavily on the combination of in vitro and in vivo methods to assess the safety and efficacy of nanotechnology platforms, nanoparticle-formulated drugs, and vaccines. While certain types of toxicities can be evaluated in vitro and good in vitro–in vivo correlation has been demonstrated for such tests, animal studies are still needed to address complex biological questions and, therefore, provide a unique contribution to establishing nanoparticle safety and efficacy profiles. The genetic, metabolic, mechanistic, and phenotypic diversity of currently available animal models often complicates both the animal choice and the interpretation of the results. This review summarizes current knowledge about differences in the immune system function and immunological responses of animals commonly used in preclinical studies of nanomaterials. We discuss challenges, highlight current gaps, and propose recommendations for animal model selection to streamline preclinical analysis of nanotechnology formulations.",
keywords = "Allergy, Anaphylaxis, Animals, Complement, Cytokine storm, Inflammation, Macrophages, MPS, Nanoparticles",
author = "Zamboni, {William C.} and J. Szebeni and Kozlov, {Serguei V.} and Lucas, {Andrew T.} and Piscitelli, {Joseph A.} and Dobrovolskaia, {Marina A.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.addr.2018.09.012",
language = "English",
journal = "Advanced Drug Delivery Reviews",
issn = "0169-409X",
publisher = "Elsevier",

}

TY - JOUR

T1 - Animal models for analysis of immunological responses to nanomaterials

T2 - Challenges and considerations

AU - Zamboni, William C.

AU - Szebeni, J.

AU - Kozlov, Serguei V.

AU - Lucas, Andrew T.

AU - Piscitelli, Joseph A.

AU - Dobrovolskaia, Marina A.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Nanotechnology provides many solutions to improve conventional drug delivery and has a unique niche in the areas related to the specific targeting of the immune system, such as immunotherapies and vaccines. Preclinical studies in this field rely heavily on the combination of in vitro and in vivo methods to assess the safety and efficacy of nanotechnology platforms, nanoparticle-formulated drugs, and vaccines. While certain types of toxicities can be evaluated in vitro and good in vitro–in vivo correlation has been demonstrated for such tests, animal studies are still needed to address complex biological questions and, therefore, provide a unique contribution to establishing nanoparticle safety and efficacy profiles. The genetic, metabolic, mechanistic, and phenotypic diversity of currently available animal models often complicates both the animal choice and the interpretation of the results. This review summarizes current knowledge about differences in the immune system function and immunological responses of animals commonly used in preclinical studies of nanomaterials. We discuss challenges, highlight current gaps, and propose recommendations for animal model selection to streamline preclinical analysis of nanotechnology formulations.

AB - Nanotechnology provides many solutions to improve conventional drug delivery and has a unique niche in the areas related to the specific targeting of the immune system, such as immunotherapies and vaccines. Preclinical studies in this field rely heavily on the combination of in vitro and in vivo methods to assess the safety and efficacy of nanotechnology platforms, nanoparticle-formulated drugs, and vaccines. While certain types of toxicities can be evaluated in vitro and good in vitro–in vivo correlation has been demonstrated for such tests, animal studies are still needed to address complex biological questions and, therefore, provide a unique contribution to establishing nanoparticle safety and efficacy profiles. The genetic, metabolic, mechanistic, and phenotypic diversity of currently available animal models often complicates both the animal choice and the interpretation of the results. This review summarizes current knowledge about differences in the immune system function and immunological responses of animals commonly used in preclinical studies of nanomaterials. We discuss challenges, highlight current gaps, and propose recommendations for animal model selection to streamline preclinical analysis of nanotechnology formulations.

KW - Allergy

KW - Anaphylaxis

KW - Animals

KW - Complement

KW - Cytokine storm

KW - Inflammation

KW - Macrophages

KW - MPS

KW - Nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=85054349608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054349608&partnerID=8YFLogxK

U2 - 10.1016/j.addr.2018.09.012

DO - 10.1016/j.addr.2018.09.012

M3 - Article

AN - SCOPUS:85054349608

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

SN - 0169-409X

ER -